2 results
Approved WMOCompleted
The first objective is to evaluate the superiority of CHF 5259 pMDI (glycopyrrolate bromide) (50 µg total daily dose) versus placebo in terms of FEV1 AUC0-12h normalised by time on Day 42.Key Secondary objectiveTo evaluate the superiority of CHF…
Approved WMORecruiting
We aim to prevent or reverse developmental regression in patients with Kleefstra syndrome. We hypothesise that the regression we observed is the result of a psychotic disorder, which isnot properly recognised by clinicians and often not treated…